Quarterly report pursuant to Section 13 or 15(d)

Stockholder's Equity (Details Narrative)

v3.20.2
Stockholder's Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 17, 2020
Aug. 17, 2020
Aug. 16, 2020
Apr. 02, 2020
Apr. 02, 2020
Feb. 07, 2020
Mar. 31, 2020
Jul. 31, 2019
Sep. 30, 2020
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
May 04, 2017
Common stock, shares authorized                 50,000,000 50,000,000   45,000,000  
Common stock, par value                 $ 0.0001 $ 0.0001   $ 0.0001  
Common stock, shares issued                 14,282,736 14,282,736   10,404,342  
Common stock, shares outstanding                 14,282,736 14,282,736   10,404,342  
Preferred stock, shares authorized                    
Preferred stock, par value                    
Preferred stock, shares issued                    
Preferred stock, shares outstanding                    
Warrants price                         $ 0.50
Warrants exercised         $ 935,000                
True-Up Payment [Member]                          
Number of warrants issued to purchase common stock 134,000 134,000                      
Warrant exercisable per share $ 1.25 $ 1.25                      
Warrant expiration date   Aug. 31, 2025                      
Warrants value $ 28,060 $ 28,060                      
Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Stock options granted                   400,010      
Warrants price             $ 0.50            
Deemed dividend             $ 325,000            
Warrants exercised             $ 1,200,000            
Sonnet BioTherapeutics, Inc [Member]                          
Subscription price       $ 0.01 $ 0.01                
Number of warrants issued to purchase common stock       186,161 186,161                
Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Warrants price       $ 1.25 $ 1.25                
Warrants exercised       $ 350,000                  
Redeemed warrants, shares       261,050                  
Redeemed warrants, value       $ 66,900                  
Warrants remained shares       525,554                  
Convertible note agreement percentage       10.00%                  
Warrant issued description       Additionally, 3,275,200 warrants were issued of which 2,925,200 warrants were issued with an exercise price ranging between $.125 and $.5 in connection with the issuance of the Company's 10% convertible note agreement and 350,000 warrants with an exercise price of $.125 were issued to the Company's bridge financing investor.                  
Maximum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Stock price volatility             95.00%            
Risk-free interest rates             84.00%            
Weighted average term             8 years            
Maximum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Warrants price       $ 0.5 0.5                
Minimum [Member] | Chanticleer Holdings, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Stock price volatility             88.00%            
Risk-free interest rates             1.70%            
Weighted average term             6 years 6 months            
Minimum [Member] | Sonnet BioTherapeutics, Inc [Member] | 2014 Stock Incentive Plan [Member]                          
Warrants price       $ 1.25 $ 1.25                
2019 Rights Offering [Member]                          
Subscription price                       $ 1.00  
Common stock were issued               1,894,308          
Subscription shares               $ 4,190,524          
Rights offering expiration date               Jun. 28, 2019          
Gross proceeds from rights offering               $ 6,009,733          
Outstanding debt obligations               3,075,000          
Remaining proceeds from the rights offering               $ 2,700,000          
2019 Rights Offering [Member] | Chardan Capital Markets, LLC and The Oak Ridge Financial Services Group Inc [Member]                          
Percentage of gross proceeds of rights offering               7.00%          
Reimburse expenses               $ 75,000          
Sales commission               286,000          
2019 Rights Offering [Member] | Maximum [Member]                          
Subscription shares               $ 6,084,728          
2020 Bridge Financing [Member]                          
Fair value of the derivative liability                 $ 1,195,724 $ 1,195,724      
Conversion price                 $ 0.50 $ 0.50      
Convertible Preferred Stock: Series 2 [Member]                          
Preferred stock, shares authorized                 1,500 1,500    
Preferred stock, par value                 $ 1,000 $ 1,000   $ 1,000  
Preferred stock, shares issued                 787 787    
Preferred stock, shares outstanding                 787 787    
Convertible Preferred Stock: Series 2 [Member] | Maximum [Member] | Securities Purchase Agreement [Member]                          
Common stock were issued           1,500              
Common stock were issued value           $ 1,500,000              
Convertible Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member] | Securities Purchase Agreement [Member]                          
Preferred stock, shares issued                     713    
Stock issued during period conversion of convertible securities             1,426,854            
Convertible Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member] | Chanticleer [Member] | Securities Purchase Agreement [Member]                          
Common stock, par value           $ 1.25              
Sale of stock, number of shares           1,500              
Gross proceeds preference stock           $ 1,500,000              
Sale of stock, transaction costs           $ 95,000              
Warrants term           5 years              
Warrants to purchase common stock           350,000              
Preferred stock value           $ 1,000              
Embedded derivative liability           529,000              
Beneficial conversion feature           $ 729,000              
Convertible Preferred Stock: Series 1 [Member]                          
Preferred stock, shares outstanding                       62,876  
Series 2 Preferred Stock [Member]                          
Cash payment to stock holders $ 66,000                        
Number of warrants issued to purchase common stock 134,000 134,000                      
Common stock were issued value $ 28,060                        
Preferred Stock: Series 2 [Member] | 2020 Bridge Financing [Member]                          
Stock issued during period conversion of convertible securities                   1,400      
Common stock were issued value                   $ 1,250,000      
Percentage of cash equal to dollar value                   1.25%      
Trigger default interest rate                   18.00%      
Fair value of the derivative liability                 $ 529,000 $ 529,000      
Increase (decrease) in derivative liabilities     $ 666,724           $ 243,759        
Conversion price                 $ 1.00 $ 1.00      
Beneficial ownership percentage limitation                 4.99% 4.99%      
Percentage of limitation prior to merger                   9.99%